Conv. Plasma
Nigella Sativa

All colchicine studies
Meta analysis
study COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality, after 14 day foll.. 81% Improvement Relative Risk Mortality, in hospital 89% ICU admission 87% Hospitalization time 35% Colchicine  Vaziri et al.  LATE TREATMENT  RCT Is late treatment with colchicine + phenolic monoterpenes beneficial for COVID-19? RCT 179 patients in Iran (April - December 2020) Lower mortality (p=0.03) and ICU admission (p=0.0019) Vaziri et al., Heliyon, March 2024 Favors colchicine Favors control

Investigating efficacy of colchicine plus phenolic monoterpenes fraction as a potential treatment for patients diagnosed with COVID-19: A randomized controlled parallel clinical trial

Mar 2024  
  Source   PDF   All   Meta
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
*, now known with p = 0.0000001 from 54 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments.
RCT 179 hospitalized COVID-19 patients showing lower mortality, ICU admission, and hospitalization duration with colchicine plus phenolic monoterpenes compared to standard care alone. The intervention group received 0.8 mg/day colchicine and 45 mg/day phenolic monoterpenes extracted from nigella sativa and Trachyspermum ammi in addition to standard care (lopinavir/ritonavir). No serious side effects were reported. Baseline SpO2 was significantly lower in the control group, although there was no significant difference in severity according to NIH guidelines.
This study is excluded in the after exclusion results of meta analysis: randomization resulted in significant baseline differences that were not adjusted for.
Study covers nigella sativa and colchicine.
risk of death, 81.2% lower, RR 0.19, p = 0.03, treatment 2 of 108 (1.9%), control 7 of 71 (9.9%), NNT 12, after 14 day followup.
risk of death, 89.0% lower, RR 0.11, p = 0.02, treatment 1 of 108 (0.9%), control 6 of 71 (8.5%), NNT 13, in hospital.
risk of ICU admission, 86.9% lower, RR 0.13, p = 0.002, treatment 2 of 108 (1.9%), control 10 of 71 (14.1%), NNT 8.2.
hospitalization time, 34.7% lower, relative time 0.65, p < 0.001, treatment mean 4.17 (±1.34) n=108, control mean 6.39 (±2.59) n=71.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Vaziri et al., 6 Mar 2024, Randomized Controlled Trial, Iran, peer-reviewed, mean age 54.2, 11 authors, study period April 2020 - December 2020, this trial uses multiple treatments in the treatment arm (combined with phenolic monoterpenes) - results of individual treatments may vary, trial NCT04392141 (history). Contact:
This PaperColchicineAll
Investigating efficacy of colchicine plus phenolic monoterpenes fraction as a potential treatment for patients diagnosed with COVID-19: A randomized controlled parallel clinical trial
Siavash Vaziri, Alireza Janbakhsh, Mohammad Hossein Zamanian, Yadollah Shakiba, Shayan Mostafaei, Amir Hossein Norooznezhad, Kamran Mansouri, Ph.D Ahmad Bagheri, Farhad Abdali, Kavyan Fatahpour, Ali Mostafaie
Heliyon, doi:10.1016/j.heliyon.2024.e27373
Background: COVID-19 now is a serious concern for the world healthcare system. This study aimed to investigate possible therapeutic effect of colchicine and phenolic monoterpenes accompanied by standard care of treatment (SCT) in patients diagnosed with COVID-19. Methods: In this randomized controlled parallel clinical trial, a total number of 179 (of 200) patients with confirmed COVID-19 were enrolled according to the inclusion and exclusion criteria. The patients were allocated by simple randomization method into two groups control (receiving SCT with 71 patients) and intervention (receiving SCT plus colchicine and phenolic monoterpenes with 107 patients). The mortality ratio during hospitalization as well as a 2-week follow-up, ICU admission rate, and hospitalization duration were assessed as main outcomes. Results: The mortality ratio was 0.9% (1/108) and 8.45% (6/71) in the intervention and the control groups (p-value= 0.035) respectively, these ratios after a 14-day follow-up were 1.85% (2/108), and 9.85 (7/71) respectively (p-value= 0.031). Also, the ICU admission was significantly lower (p-value= 0.006) in the intervention group 2/108 (1.85%) compared with controls 10/71 (14.08%). Moreover, the duration of hospitalization followed a similar pattern to ICU admission with 4.17 ± 1.34 vs. 6.39 ± 2.59 days in the intervention and control groups respectively (p-value< 0.001). Furthermore, no significant side effect was found between the groups. Conclusion: According to the results, the combination of colchicine plus phenolic monoterpenes could be an additive treatment for the SCT. The authors strongly recommend further trials on this combination with other SCTs.
Conflict of interest Prof. Ali Mostafaie and Mr. Kavyan Fattahipour are employees of Zist Tolid Razi Co. Other authors declare no actual or potential conflict of interest. J o u r n a l P r e -p r o o f
Ang, Song, Lee, Lee, Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials, J Clin Med
De Las Heras, Martín Giménez, Ferder, Manucha, Lahera, Implications of Oxidative Stress and Potential Role of Mitochondrial Dysfunction in COVID-19: Therapeutic Effects of Vitamin D, Antioxidants
Deftereos, Giannopoulos, Vrachatis, Siasos, Giotaki et al., Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA New Open
Hantoushzadeh, Norooznezhad, Inappropriate Antibiotic Consumption as a Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed with Coronavirus-19 Disease (COVID-19), Arch Med Res
J O U R N A L P R E, None
J O U R N A L P R E, None
Koshak, Koshak, Mobeireek, Badawi, Wali et al., Nigella sativa supplementation to treat symptomatic mild COVID-19: A structured summary of a protocol for a randomised, controlled, clinical trial, Trials
Leung, Hui, Kraus, Colchicine--Update on mechanisms of action and therapeutic uses, Semin Arthritis Rheum
Libby, Lüscher, COVID-19 is, in the end, an endothelial disease, Eur Heart J
Lopes, Bonjorno, Giannini, Amaral, Menezes et al., Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial, RMD Open
Norooznezhad, Eskandarion, Akbari, Alimohammadi, Nabavian et al., Changes of Leukocytes, Neutrophils, and Lymphocytes Count and Dependent Variables in Pregnant Women with Coronavirus Disease 2019 (COVID-19) Before and After Cesarean Delivery, J Med Virol
Norooznezhad, Najafi, Riahi, Moradinazar, Shakiba et al., Primary Symptoms, Comorbidities, and Outcomes of 431 Hospitalized Patients with Confirmative RT-PCR Results for COVID-19, Am J Trop Med Hyg
Shaterzadeh-Yazdi, Noorbakhsh, Hayati, Samarghandian, Farkhondeh, Immunomodulatory and Anti-inflammatory Effects of Thymoquinone, Cardiovasc Hematol Disord Drug Targets
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
{ 'DOI': '10.1016/j.heliyon.2024.e27373', 'ISSN': ['2405-8440'], 'URL': '', 'alternative-id': ['S2405844024034042'], 'article-number': 'e27373', 'assertion': [ {'label': 'This article is maintained by', 'name': 'publisher', 'value': 'Elsevier'}, { 'label': 'Article Title', 'name': 'articletitle', 'value': 'Investigating efficacy of colchicine plus phenolic monoterpenes fraction as a ' 'potential treatment for patients diagnosed with COVID-19: A randomized ' 'controlled parallel clinical trial'}, {'label': 'Journal Title', 'name': 'journaltitle', 'value': 'Heliyon'}, { 'label': 'CrossRef DOI link to publisher maintained version', 'name': 'articlelink', 'value': ''}, {'label': 'Content Type', 'name': 'content_type', 'value': 'article'}, { 'label': 'Copyright', 'name': 'copyright', 'value': '© 2024 The Authors. Published by Elsevier Ltd.'}], 'author': [ {'affiliation': [], 'family': 'Vaziri', 'given': 'Siavash', 'sequence': 'first'}, {'affiliation': [], 'family': 'Janbakhsh', 'given': 'Alireza', 'sequence': 'additional'}, { 'affiliation': [], 'family': 'Zamanian', 'given': 'Mohammad Hossein', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Shakiba', 'given': 'Yadollah', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Mostafaei', 'given': 'Shayan', 'sequence': 'additional'}, { 'affiliation': [], 'family': 'Norooznezhad', 'given': 'Amir Hossein', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Mansouri', 'given': 'Kamran', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Bagheri', 'given': 'Ahmad', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Abdali', 'given': 'Farhad', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Fatahpour', 'given': 'Kavyan', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Mostafaie', 'given': 'Ali', 'sequence': 'additional'}], 'container-title': 'Heliyon', 'container-title-short': 'Heliyon', 'content-domain': { 'crossmark-restriction': True, 'domain': ['', '', '']}, 'created': {'date-parts': [[2024, 3, 6]], 'date-time': '2024-03-06T08:28:28Z', 'timestamp': 1709713708000}, 'deposited': { 'date-parts': [[2024, 3, 6]], 'date-time': '2024-03-06T08:28:35Z', 'timestamp': 1709713715000}, 'indexed': {'date-parts': [[2024, 3, 7]], 'date-time': '2024-03-07T00:33:10Z', 'timestamp': 1709771590804}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2024, 3]]}, 'language': 'en', 'license': [ { 'URL': '', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2024, 3, 1]], 'date-time': '2024-03-01T00:00:00Z', 'timestamp': 1709251200000}}, { 'URL': '', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2024, 2, 28]], 'date-time': '2024-02-28T00:00:00Z', 'timestamp': 1709078400000}}], 'link': [ { 'URL': '', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': '', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'member': '78', 'original-title': [], 'page': 'e27373', 'prefix': '10.1016', 'published': {'date-parts': [[2024, 3]]}, 'published-print': {'date-parts': [[2024, 3]]}, 'publisher': 'Elsevier BV', 'reference': [ { 'DOI': '10.4269/ajtmh.20-0512', 'article-title': 'Primary symptoms, comorbidities, and outcomes of 431 hospitalized ' 'patients with confirmative RT-PCR results for COVID-19', 'author': 'Norooznezhad', 'doi-asserted-by': 'crossref', 'first-page': '834', 'journal-title': 'Am. J. Trop. Med. Hyg.', 'key': '10.1016/j.heliyon.2024.e27373_bib1', 'volume': '103', 'year': '2020'}, { 'DOI': '10.1016/j.arcmed.2020.03.015', 'article-title': 'Inappropriate antibiotic consumption as a possible cause of ' 'inflammatory storm and septic shock in patients diagnosed with ' 'coronavirus-19 disease (COVID-19)', 'author': 'Hantoushzadeh', 'doi-asserted-by': 'crossref', 'first-page': '347', 'journal-title': 'Arch. Med. Res.', 'key': '10.1016/j.heliyon.2024.e27373_bib2', 'volume': '51', 'year': '2020'}, { 'DOI': '10.1016/S0140-6736(20)30566-3', 'article-title': 'Clinical course and risk factors for mortality of adult inpatients with ' 'COVID-19 in Wuhan, China: a retrospective cohort study', 'author': 'Zhou', 'doi-asserted-by': 'crossref', 'first-page': '1054', 'journal-title': 'Lancet', 'key': '10.1016/j.heliyon.2024.e27373_bib3', 'volume': '395', 'year': '2020'}, { 'DOI': '10.1002/jmv.26525', 'article-title': 'Changes of leukocytes, neutrophils, and lymphocytes count and dependent ' 'variables in pregnant women with coronavirus disease 2019 (COVID-19) ' 'before and after cesarean delivery', 'author': 'Norooznezhad', 'doi-asserted-by': 'crossref', 'first-page': '664', 'journal-title': 'J. Med. Virol.', 'key': '10.1016/j.heliyon.2024.e27373_bib4', 'volume': '2', 'year': '2021'}, { 'DOI': '10.3390/jcm9051583', 'article-title': 'Herbal medicine for the treatment of coronavirus disease 2019 ' '(COVID-19): a systematic review and meta-analysis of randomized ' 'controlled trials', 'author': 'Ang', 'doi-asserted-by': 'crossref', 'first-page': '1583', 'journal-title': 'J. Clin. Med.', 'key': '10.1016/j.heliyon.2024.e27373_bib5', 'volume': '9', 'year': '2020'}, { 'key': '10.1016/j.heliyon.2024.e27373_bib6', 'series-title': 'Definitions of Symptoms for Reportable Illnesses', 'year': '2020'}, { 'key': '10.1016/j.heliyon.2024.e27373_bib8', 'series-title': 'Management of Persons with COVID-19', 'year': '2020'}, { 'article-title': 'Effect of colchicine vs standard care on cardiac and inflammatory ' 'biomarkers and clinical outcomes in patients hospitalized with ' 'coronavirus disease 2019: the GRECCO-19 randomized clinical trial', 'author': 'Deftereos', 'journal-title': 'JAMA New Open', 'key': '10.1016/j.heliyon.2024.e27373_bib9', 'volume': '3', 'year': '2020'}, { 'DOI': '10.1136/rmdopen-2020-001455', 'article-title': 'Beneficial effects of colchicine for moderate to severe COVID-19: a ' 'randomised, double-blinded, placebo-controlled clinical trial', 'author': 'Lopes', 'doi-asserted-by': 'crossref', 'journal-title': 'RMD Open', 'key': '10.1016/j.heliyon.2024.e27373_bib10', 'volume': '7', 'year': '2021'}, { 'DOI': '10.1186/s13063-020-04647-x', 'article-title': 'Nigella sativa supplementation to treat symptomatic mild COVID-19: a ' 'structured summary of a protocol for a randomised, controlled, clinical ' 'trial', 'author': 'Koshak', 'doi-asserted-by': 'crossref', 'first-page': '703', 'journal-title': 'Trials', 'key': '10.1016/j.heliyon.2024.e27373_bib11', 'volume': '21', 'year': '2020'}, { 'DOI': '10.1016/j.semarthrit.2015.06.013', 'article-title': 'Colchicine--Update on mechanisms of action and therapeutic uses', 'author': 'Leung', 'doi-asserted-by': 'crossref', 'first-page': '341', 'journal-title': 'Semin. Arthritis Rheum.', 'key': '10.1016/j.heliyon.2024.e27373_bib12', 'volume': '45', 'year': '2015'}, { 'DOI': '10.2174/1871529X18666180212114816', 'article-title': 'Immunomodulatory and anti-inflammatory effects of thymoquinone', 'author': 'Shaterzadeh-Yazdi', 'doi-asserted-by': 'crossref', 'first-page': '52', 'journal-title': 'Cardiovasc. Hematol. Disord.: Drug Targets', 'key': '10.1016/j.heliyon.2024.e27373_bib13', 'volume': '18', 'year': '2018'}, { 'DOI': '10.3390/antiox9090897', 'article-title': 'Implications of oxidative stress and potential role of mitochondrial ' 'dysfunction in COVID-19: therapeutic effects of vitamin D', 'author': 'de Las Heras', 'doi-asserted-by': 'crossref', 'first-page': '897', 'journal-title': 'Antioxidants', 'key': '10.1016/j.heliyon.2024.e27373_bib14', 'volume': '9', 'year': '2020'}, { 'DOI': '10.1093/eurheartj/ehaa623', 'article-title': 'COVID-19 is, in the end, an endothelial disease', 'author': 'Libby', 'doi-asserted-by': 'crossref', 'first-page': '3038', 'journal-title': 'Eur. Heart J.', 'key': '10.1016/j.heliyon.2024.e27373_bib15', 'volume': '41', 'year': '2020'}], 'reference-count': 14, 'references-count': 14, 'relation': {}, 'resource': {'primary': {'URL': ''}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Multidisciplinary'], 'subtitle': [], 'title': 'Investigating efficacy of colchicine plus phenolic monoterpenes fraction as a potential ' 'treatment for patients diagnosed with COVID-19: A randomized controlled parallel clinical trial', 'type': 'journal-article', 'update-policy': ''}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop